Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT

Jul 8, 2025 - 21:01

0

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT

Related Posts

US miners eye copper comeback as demand rises

US miners eye copper comeback as demand rises

Mar 24, 2025 0

Segway recalls 220,000 scooters after consumers report injuries, including broken bones

Segway recalls 220,000 scooters after consumers report ...

Mar 24, 2025 0

Risks of buy now, pay later: 'Ticket to overspending,' expert says

Risks of buy now, pay later: 'Ticket to overspending,' ...

Mar 24, 2025 0

U.S. coffee drinkers can expect rising prices as perfect storm of factors impact global supply chains

U.S. coffee drinkers can expect rising prices as perfec...

Mar 24, 2025 3

23andMe files for bankruptcy as California AG urges customers to delete data

23andMe files for bankruptcy as California AG urges cus...

Mar 24, 2025 0

Federal judge blocks DOGE from personal data, in another injunction against Trump

Federal judge blocks DOGE from personal data, in anothe...

Mar 24, 2025 0